January 21 | 2021
Last patient treated in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment.
Read more
January 5 | 2021
2cureX appoints Fernando Andreu, an international Biotech executive, as new CEO
Read more
December 23 | 2020
Key achievements in 2020 – an IndiTreat ® Launch year
Read more
November 26 | 2020
2cureX offentliggör delårsrapport för det tredje kvartalet 2020.
Read more
November 26 | 2020
2cureX publishes interim report for the third quarter of 2020.
Read more
November 26 | 2020
2cureX launches new website
Read more
November 11 | 2020
2cureX presents commercial roadmap 2021 – 2023
Read more
November 11 | 2020
2cureX presents commercial roadmap 2021 – 2023
Read more
November 5 | 2020
Announcement from 2cureX extra general meeting
Read more
November 5 | 2020
Kommuniké från extra bolagsstämma i 2cureX
Read more
October 14 | 2020
Notice of extraordinary general meeting in 2ureX AB
Read more
October 14 | 2020
Kallelse till extra bolagsstämma i 2cureX AB
Read more
October 1 | 2020
Den sista patienten är registrerad med framgång i världens första interventionsstudie med 3D-mikrotumörer som vägledning för val av cancerbehandling.
Read more
October 1 | 2020
Last patient successfully enrolled in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment.
Read more
September 14 | 2020
2cureX launches world’s first CE-marked microtumor test service
Read more
September 14 | 2020
2cureX launches world’s first CE-marked microtumor test service
Read more
August 27 | 2020
2cureX AB (“2cureX”) hereby publishes the interim report for the first half of 2020.
Read more
August 27 | 2020
2cureX AB (”2cureX”) offentliggör härmed halvårsrapport för det första halvåret 2020
Read more